International | Great Britain

Biotest AG / Preliminary Results


Ad hoc announcement according to § 15 WpHG transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Increase in sales and earnings in financial year 2006 higher than expected

Dreieich, 14 February 2007. According to unaudited figures, Biotest Group
sales were 18.7% up on the previous year (EUR 237.6 million) to EUR 281.9
million. At EUR 31.4 million, earnings before interest and taxes (EBIT)
were 24.1% higher than in financial year 2005 (EUR 25.3 million), with an
improvement in profit before tax from EUR 15.0 million to EUR 21.6 million
(+43.9%). Group net profit excluding minority interests rose by 57.3% to
EUR 16.0 million (previous year: EUR 10.2 million) to generate earnings per
share amounting to EUR 1.48 (previous year: EUR 1.13). Consequently, growth
has surpassed the expectations of the Management.In the Pharmaceutical
segment, sales rose 27.9% to EUR 205.1 million (previous year: EUR 160.4
million), and in the Diagnostic segment, sales fell slightly to EUR 76.8
million (previous year: EUR 77.2 million).In spite of the significant
increase in the level of research and development costs, the operating
margin before interest and taxes rose from 10.6% to 11.1%. To a large
extent, the improvement in the results is attributable to the success of
the plasma protein business, while the Diagnostic segment closed with
slightly negative EBIT.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich,
Dr. Michael Ramroth, Telefon: +49 (0) 6103 801-338, E-Mail:
Dr. Marion Wendorff, Telefon: +49 (0) 6103 801-520, E-Mail:
Telefax: +49 (0) 6103 801-347

DGAP 14.02.2007

Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich Deutschland
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart

End of News DGAP News-Service